With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.75336-86-6,(R)-2-Methylpiperazine,as a common compound, the synthetic route is as follows.
75336-86-6, Intermediate 15;: (3R)-3-methyl-l-[5-(trifluoromethyl)pyridin-2-yl]piperazine; NA suspension of 2-bromo-5-trifluoromethyl-pyridine (2.37 g; 10.0 mmol; 1.0 eq.), (R)-2-methylpiperazine (2.00 g; 20.0 mmol; 2.0 eq.) and DIEA (1.94 g; 15.0 mmol; 1.5 eq.) in 4 mL of DMA was heated at 140°C for 14h. The mixture was cooled to room temperature. After evaporation of the solvent under vacuum, the residue was dissolved in a 1/1 mixture of DCM / Et2O. A 4N solution of HC1 was added (10 mL) then the resulting precipitate was collected and washed with Et2O. The solid was then poured to an aq. solution of NaOH (5N, 20 mL) and the resulting mixture was extracted with Et2O (3X). The combined organic layers were washed with brine, dried over MgSC>4, filtered and evaporated to give the title compound as an orange solid (1680 mg, 69percent) used without further purification for the next steps. M+(ESI): 246.3. HPLC (Condition A), Rt: 1.0 min (HPLC purity: 99.9 percent).
As the paragraph descriping shows that 75336-86-6 is playing an increasingly important role.
Reference：
Patent; Applied Research Systems ARS Holding N.V.; WO2006/10751; (2006); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics